Jan 29, 2021
Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China
Jan 28, 2021
Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results
Jan 26, 2021
Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer
Jan 11, 2021
Amgen To Achieve Carbon Neutrality By 2027
Jan 11, 2021
Amgen To Achieve Carbon Neutrality By 2027
Dec 22, 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Dec 22, 2020
Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health
Dec 22, 2020
Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency
Dec 17, 2020
FDA Approves Amgen's RIABNI(TM) (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
Dec 17, 2020
Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral
Dec 16, 2020
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
Dec 16, 2020
Amgen Announces 10% Increase In 2021 First Quarter Dividend
Dec 16, 2020
Amgen To Transfer Listing Of Debt Securities To Nasdaq
Dec 08, 2020
Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation
Dec 05, 2020
Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE® Therapy AMG 701 At ASH 2020
Dec 03, 2020
Amgen To Webcast Investor Call At ASH 2020
Nov 30, 2020
World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
Nov 25, 2020
Amgen To Present At The Evercore ISI Virtual HealthCONx Conference
Nov 23, 2020
Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics
Nov 10, 2020
Amgen To Present At The Cowen 4th Annual IO Summit